Eyegate Pharmaceuticals, Inc. Warrants
EYEGW
EYEGW was delisted on the 5th of August, 2020.
4 hedge funds and large institutions have $16K invested in Eyegate Pharmaceuticals, Inc. Warrants in 2017 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 0 reducing their positions, and 2 closing their positions.
20% less funds holding
Funds holding: 5 → 4 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
68% less capital invested
Capital invested by funds: $50K → $16K (-$34K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
+$5.93K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ICM
Ionic Capital Management
New York
|
-$20K |
| 2 |
BlackRock
New York
|
-$7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIC
1
AWM Investment Company
New York
| $11K | – | – | – |
|
|
VKH
2
Virtu KCG Holdings
New York
| $4K | +$5.93K | +38,136 | New |
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $1K | – | – | – |
|
|
ICM
4
Ionic Capital Management
New York
| – | -$20K | -133,097 | Closed |
|
|
5
BlackRock
New York
| – | -$7K | -46,688 | Closed |
|
EYEGW Hedge Fund Activity: Q2 2017 in Review
4 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Eyegate Pharmaceuticals, Inc. Warrants (EYEGW) for Q2 2017, worth a combined $16K — down 68% from $50K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of EYEGW and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest buyer was Virtu KCG Holdings, opening a new position worth an estimated $5.93K. The largest seller was Ionic Capital Management, exiting entirely with an estimated $20K sold.
- 4 institutional investors held Eyegate Pharmaceuticals, Inc. Warrants (EYEGW) as of Q2 2017, down from 5 in Q1 2017.
- Funds reported $16K of Eyegate Pharmaceuticals, Inc. Warrants stock for Q2 2017, down 68% quarter-over-quarter.
- 1 fund opened new Eyegate Pharmaceuticals, Inc. Warrants positions in Q2 2017 and 2 closed out, a net change of -1 holder.
- The largest Eyegate Pharmaceuticals, Inc. Warrants buyer in Q2 2017 was Virtu KCG Holdings, an estimated $5.93K added.
- The largest Eyegate Pharmaceuticals, Inc. Warrants seller in Q2 2017 was Ionic Capital Management, an estimated $20K sold.
Based on aggregated 13F filings for Q2 2017.